Nuclear Medicine Radioisotopes Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Nuclear Medicine Radioisotopes Market is Segmented by Type of Radioisotope (Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Iodine (I-123), Fluorine-18, Rubidium-82 (Rb-82), Iodine-131 (I-131), Lutetium-177 (Lu-177), Radium-223 (Ra-223) and Alpha Radin, Actinium-225 (Ac-225), and Other Types of Radioisotopes), Application (Oncology, Cardiology, Thyroid, Neurology, and Other Applications), and Geography (North America, Europe, Asia-Pacific, and Rest of the World). The Market Report Also Covers the Estimated Market Sizes and Trends for 17 Countries Across Major Regions Globally. The Report Offers the Value in USD for the Above Segments.

Nuclear Medicine Radioisotopes Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Nuclear Medicine Radioisotopes Industry Overview

The nuclear medicine radioisotopes market is moderately competitive, with high competition. The market players are adopting various strategies such as product launches mergers and acquisition to expand the market share. The key players operating in the market include NTP Radioisotopes SOC Ltd, Bayer AG, GE Healthcare, Nordion Inc. (Sotera Health Company), and Cardinal Health Inc.

Nuclear Medicine Radioisotopes Market Leaders

  1. NTP Radioisotopes SOC Ltd

  2. Bayer AG

  3. GE Healthcare

  4. Nordion Inc. (Sotera Health Company)

  5. Cardinal Health Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Nuclear Medicine Radioisotopes Market Concentration

Nuclear Medicine Radioisotopes Market Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?